Biotechnology Industry News: Industry Center – Yahoo Finance

Latest News Sunday, Jun 5, 2016 Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 SPEAR T-Cells in Multiple Cancers at the 2016 Annual American Society of Clinical Oncology (ASCO) Meeting GlobeNewswire - Sun 9:05 am ET Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting Business Wire - Sun 9:05 am ET Mirati Therapeutics Provides Progress Update On Current Clinical Trials PR Newswire - Sun 9:00 am ET Oncothyreon Presents Phase 1b Results of ONT-380 in Combination with T-DM1 in HER2+ Metastatic Breast Cancer at ASCO GlobeNewswire - Sun 9:00 am ET Ignyta Announces Interim Data from Phase 1 Clinical Trial of Investigational Precision Medicine RXDX-105 at ASCO 2016 Business Wire - Sun 9:00 am ET OncoMed Presents Phase 1b Data for First-in-Class Treatments in Ovarian, Breast and Lung Cancer at the 2016 ASCO Annual Meeting GlobeNewswire - Sun 9:00 am ET Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO Business Wire - Sun 7:35 am ET J&J myeloma drug, in combo regimen, delays worsening of the disease Reuters - Sun 7:30 am ET Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting Business Wire - Sun 7:30 am ET Stemline Therapeutics SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at ASCO; High Response Rates Demonstrated Across All Lines As Enrollment Proceeds GlobeNewswire - Sat 7:07 pm ET TESARO Provides Pipeline Update at ASCO Investor Briefing GlobeNewswire - Sat 7:00 pm ET Data Presented at ASCO 2016 Builds upon Foundation of Abraxane Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer Business Wire - Sat 5:32 pm ET Juno Therapeutics Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates in Adults with B-cell ALL Business Wire - Sat 5:15 pm ET Saturday, Jun 4, 2016 Celldex Therapeutics CDX1401, CDX301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma GlobeNewswire - Sat 2:02 pm ET Juno Therapeutics Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability Business Wire - Sat 10:08 am ET Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting GlobeNewswire - Sat 9:24 am ET Encorafenib-based Regimens Provide Improved PFS and OS in Difficult-to-Treat BRAF-Mutant Colorectal Cancer Compared to Historical Benchmarks PR Newswire - Sat 9:00 am ET Array BioPharma, Pierre Fabre and Merck KGaA, Darmstadt, Germany Announce Phase 3 BEACON CRC Trial PR Newswire - Sat 9:00 am ET Aduro Biotech Presents Encouraging Anti-Tumor Response Data From Ongoing Phase 1b Study in Malignant Pleural Mesothelioma at ASCO GlobeNewswire - Sat 9:00 am ET Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20 PR Newswire - Sat 9:00 am ET More Latest News...

See original here:
Biotechnology Industry News: Industry Center - Yahoo Finance